AUAustralia
Foundayo approval in Australia brings a second GLP 1 pill to private scripts
The TGA has cleared Eli Lilly's daily Foundayo tablet for weight loss and type 2 diabetes, weeks after the Wegovy pill. It will be sold on private prescription only, with no PBS listing and no price disclosed.
Illustration by Peptide Global, not a picture of the place in the story.
The short of itAustralia's TGA has cleared Eli Lilly's daily Foundayo tablet for weight management and type 2 diabetes, the country's second GLP-1 pill after the Wegovy tablet.
The Foundayo approval in Australia gives patients a second daily GLP-1 pill for weight loss and type 2 diabetes, weeks after the Therapeutic Goods Administration cleared a tablet form of Wegovy. Eli Lilly's Australian arm said the drug, orforglipron, should reach pharmacies within days. It will be available only on private prescription for now, because it is not on the Pharmaceutical Benefits Scheme. Unlike semaglutide, Foundayo is a small molecule rather than a peptide, and Lilly says it can be taken at any time without food or water restrictions.
What the TGA cleared
The decision covers weight management and type 2 diabetes, according to 7NEWS, which reported the approval and Lilly's statements. Foundayo works on the same GLP-1 receptor as Ozempic and Wegovy, reducing hunger and slowing digestion, but it is built differently. Semaglutide is a peptide, a chain of amino acids, and in tablet form it needs help to be absorbed and has to be taken under strict fasting rules. Orforglipron is a small chemical molecule that the gut absorbs more easily, which is why Lilly can offer a once daily pill without mealtime limits. Prescribers in Australia now have two oral options built on very different chemistry.
Lilly Australia general manager Dr Manny Simons said Foundayo's clinical trials involved more than 10,000 patients in 15 countries, including a dozen Australian hospitals and clinics. "Now that Foundayo can be prescribed, our focus is on ways to deliver broader access for Australians who may benefit from this new medicine," he said. The company listed the main safety points in its statement. Digestive side effects were the most common in trials, mostly mild or moderate and more frequent while the dose was being raised. Warnings cover low blood sugar when it is used with insulin or a sulfonylurea, and pancreatitis. Lilly said Foundayo should not be used in pregnancy, and that combining it with other GLP-1 drugs is not recommended.
A second pill in a peptide market
Until recently, Australian patients seeking a GLP-1 drug for weight loss were choosing among injected peptides, mainly semaglutide and tirzepatide. The TGA's earlier clearance of oral semaglutide under the Wegovy name, part of a Wegovy pill rollout across several markets, added the first tablet. Foundayo now adds a second one from a rival maker. For people who dislike needles, the choice is no longer between a pen and nothing. For the peptide makers, it is the first time in Australia that a non peptide GLP-1 drug competes directly for the same patients, and freedom from fasting rules is Lilly's main argument against Novo Nordisk's tablet.
For people who dislike needles, the choice is no longer between a pen and nothing.
Neither company has shown how the two pills compare in a head to head trial, and the reports gave no price for either tablet. Without a subsidy, cost will fall on patients through private scripts, as it already does for many people using injected GLP-1 drugs for weight loss. The Foundayo approval in Australia does not change the rules for public funding. A medicine has to be recommended by the Pharmaceutical Benefits Advisory Committee, and the government has to agree a price, before it can be subsidised on the PBS. No recommendation for Foundayo has been reported. Until then, the pill competes on convenience and on whatever private price Lilly sets when stock reaches pharmacies.
| Item | Detail |
|---|---|
| Medicine | Foundayo, orforglipron, daily tablet |
| Maker | Eli Lilly, Australian arm |
| Regulator | Therapeutic Goods Administration |
| Uses | Weight management and type 2 diabetes |
| Availability | Pharmacies within days, private prescription |
| PBS status | Not listed |
| Trial base cited by Lilly | More than 10,000 patients in 15 countries |
| Earlier oral GLP-1 | Wegovy tablet, cleared weeks earlier |
| Price | Not disclosed |
The obesity burden behind the decision
Clinicians welcomed the decision mainly for its reach. Associate Professor Samantha Hocking, president of the National Association of Clinical Obesity Services, said overweight and obesity now affect around 13 million Australian adults. "Obesity is a complex chronic disease that increases the risk of at least 30 other serious medical conditions, ranging from cancer and cardiovascular disease to type 2 diabetes," she said. She argued that the impact on families and the health system shows the need for stronger prevention and better access to proven treatments. Her comments point to the gap the approval does not close on its own: access depends on price, and price depends on who helps pay.
For type 2 diabetes the path to subsidy is familiar. Ozempic, the injected semaglutide brand, is subsidised on the PBS for that use, and a listing for diabetes would be the more natural first step for any new GLP-1 medicine. Lilly has not said what it will seek or when. For weight management the picture is harder, because a subsidy for a large group of patients would cost the budget far more than a diabetes listing. Until there is a decision, the Foundayo approval in Australia mainly helps people who can pay privately, which is the same limit that applies to the injected drugs today. Doctors will also have to explain the differences between the two pills to patients.
What to watch next
The first marker is stock on shelves and the private price, which neither Lilly nor the reports disclosed. The second is any PBS submission and the committee meeting where it would be heard. The third is how doctors split patients between Foundayo and the Wegovy tablet. Fasting rules, side effects and cost will decide that more than marketing claims, and prescribing data will show the pattern within months. Supply is the fourth. A small molecule pill should be easier to make in large volumes than a peptide, which could help avoid the kind of shortages that hit injected semaglutide in Australia in recent years.
For readers following the Asia Pacific desk, the approval matters because Australia is now a market where the two oral approaches compete side by side, one a peptide and one a small molecule. Novo Nordisk, which built its business on peptide drugs, will watch uptake closely. Asian companies that make semaglutide ingredient are also exposed in the long run: if small molecule pills take a large share of new patients, demand for peptide ingredient would grow more slowly than it otherwise would. One approval does not settle that question, but the first Australian prescribing numbers will be among the earliest real world signs of how patients choose.
Conclusion
The Foundayo approval in Australia adds a second daily GLP-1 pill, a small molecule from Eli Lilly, weeks after the Wegovy tablet. It is available only on private prescription for now, with no price disclosed and no PBS listing. Watch the shelf price, any PBS submission and how doctors split patients between the peptide tablet and the new non peptide one.
Why it matters in Australia
Around 13 million Australian adults live with overweight or obesity. Foundayo gives them a pill without fasting rules, but only on private prescription, since it is not on the PBS and no price has been disclosed.
What to watch
The private price when stock reaches pharmacies, any PBS submission by Lilly, and how prescribers divide patients between Foundayo and the Wegovy tablet.
Sources
Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.
Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.